



SAFETY DATA SHEET

SECTION 1: PRODUCT AND COMPANY IDENTIFICATION

Product: CS-309™-30 VOC **Part Number:** 3551-300
Manufacturer: W. R. Meadows® of Canada **Address:** 70 Hannant Court
 Milton, Ontario Canada L9T 5C1
Telephone: (905) 878-4122 **In case of emergency, dial (800) 424-9300 (CHEMTREC)**
Revision Date: 8/12/2020
Product Use: Concrete Cure/Sealer

SECTION 2: HAZARDS IDENTIFICATION/EXPOSURE LIMITS

HMIS		HAZARD STATEMENTS	
Health	1	DANGER!	
Flammability	3	Highly flammable liquid and vapor.	
Reactivity	0	Harmful if Inhaled. Causes skin/eye/respiratory irritation.	
Personal Protection		Prolonged/repeated exposure may cause organ damage. May be fatal if ingested and enters airways.	

PRECAUTIONARY STATEMENTS
 Keep containers closed when not in use/avoid ignition sources.
 Avoid breathing vapors and direct contact.
 Store in well-ventilated location.
 Wear appropriate Personal Protective Equipment.
 Use only outdoors or in well-ventilated areas.

SECTION 3: HAZARDS COMPONENTS

<u>Chemical Name:</u>	<u>CAS Number</u>	<u>% by Weight</u>	<u>SARA 313</u>	<u>Vapor Pressure (mm Hg@20°C)</u>	<u>LEL (@25°C)</u>	
1. Proprietary Solvent Blend	N/E	65-70	No	N/E	N/E	<i>N/E = Not Established</i>

Under the reporting requirements of Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1966 (SARA) and 40 CFR Part 372, chemicals listed on the 313 List (40 CFR Part 373.65) are identified under the heading "SARA 313."

SECTION 4: EMERGENCY AND FIRST AID PROCEDURES

EYE CONTACT: If irritation or redness develops, move victim from exposure source and into fresh air. Flush eyes with water for fifteen (15) minutes. If symptoms persist, seek medical attention.

SKIN CONTACT: Wash affected areas with mild soap and water; remove contaminated shoes/clothing. If symptoms persist, seek medical attention.

INHALATION: If respiratory symptoms develop, move victim from exposure source and into fresh air. If symptoms persist, seek medical attention. If victim is not breathing, immediately begin artificial respiration. If breathing difficulties develop, oxygen should be administered by qualified personnel.

INGESTION: Dilute with liquid unless the victim is unconscious or very drowsy. Do not induce vomiting. If vomiting spontaneously occurs, prevent lung aspiration. Seek immediate medical attention.

MOST IMPORTANT SYMPTOMS/EFFECTS, ACUTE AND CHRONIC: See Section Eleven for Symptoms/Effects.

SECTION 5: FIRE AND EXPLOSIVES HAZARDS

FLASHPOINT: 4 °C (Estimate)

EXTINGUISHING MEDIA: Water fog, foam, dry chemical, or carbon dioxide.

CHEMICAL/COMBUSTION HAZARDS: Carbon monoxide, carbon dioxide, and incomplete combustion products.

PRECAUTIONS/PERSONAL PROTECTIVE EQUIPMENT: Avoid smoke inhalation. Personal protective equipment should include helmet, face shield, bunker coat, gloves, rubber boots, and a positive pressure NIOSH-approved self-contained breathing apparatus.

SECTION 6: ACCIDENTAL RELEASE MEASURES

SPILL OR LEAK PROCEDURES: Avoid direct contact. Dike and contain spilled material. Remove source of spill if safe to do so. Evacuate all non-essential personnel from immediate area. Remove/extinguish ignition sources. A vapor-suppressing foam may be used to reduce vapor generation. Absorb with non-combustible absorbent and place in sealed containers for disposal. Control run-off and prevent from entering waterways, sewers, etc...Use non-sparking tools to collect spilled material, as well as contaminated absorbent.

SAFETY DATA SHEET

Date of Preparation: 8/12/20

Page 2 of 3

3551-300

SECTION 7: HANDLING AND STORAGE

SAFE HANDLING PROCEDURES: Avoid direct contact. Use adequate grounding when decanting.

SAFE STORAGE: Keep containers closed when not in use. Keep away from ignition sources.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

Chemical Name:	OSHA					ACGIH		
	PEL	PEL/CEILING	PEL/STEL	SKIN	TWA	TLV/CEILING	TLV/STEL	SKIN
1. Proprietary Solvent Blend	N/E	N/E	N/E	N/E	N/E	N/E	N/E	N/E
<i>N/E: Not Established</i>								

ENGINEERING CONTROLS: Use with adequate ventilation. Use explosion-proof equipment.

PERSONAL PROTECTIVE EQUIPMENT: Safety glasses, chemical-resistant gloves.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

BOILING POINT: N/E	VAPOR DENSITY: >1 (Air=1)	% VOLATILE BY VOLUME: N/E
EVAPORATION RATE: <1 (Ether=1)	pH LEVEL: N/A	% VOLATILE BY WEIGHT: 69
WEIGHT PER GALLON: 8.17	PRODUCT APPEARANCE: Clear Liquid	VOC CONTENT: 349 g/L
ODOR: Solvent	ODOR THRESHOLD: N/D	MELTING/FREEZING POINT: N/D
FLASH POINT: See Section 5	FLAMMABILITY: N/D	UEL/LEL: N/D
VAPOR PRESSURE: N/D	RELATIVE DENSITY: N/D	SOLUBILITY: N/D
PARTITION COEFFICIENT: N/D	AUTOIGNITION TEMPERATURE: N/D	DECOMPOSITION TEMPERATURE: N/D
VISCOSITY: N/D	<i>N/E = Not Established</i>	<i>N/D = Not Determined</i>

SECTION 10: STABILITY/REACTIVITY

STABILITY: Stable.

HAZARDOUS POLYMERIZATION: Will not occur.

CONDITIONS AND MATERIALS TO AVOID: Static discharge, heat, sparks, open flame, and strong oxidizing agents.

HAZARDOUS DECOMPOSITION PRODUCTS: Carbon monoxide/dioxide, incomplete combustion products.

SECTION 11: TOXICOLOGICAL INFORMATION

EYE CONTACT: Direct contact may cause mild to moderate irritation. Product vapors may also cause irritation.

SKIN CONTACT: Direct contact may cause mild skin irritation. Prolonged/repeated contact may result in irritation/dermatitis.

INHALATION: Exposure may produce irritation to the nose, throat, respiratory tract, and other mucous membranes. Exposure to excessive vapor concentrations may cause signs of transient central nervous system depression (headache, drowsiness, loss of coordination, and fatigue). Repeated/prolonged occupational overexposures may result in permanent damage and can be potentially fatal.

INGESTION: This product is anticipated to be slightly toxic. If ingested and lung aspiration occurs, serious lung damage may result. Ingestion of excessive quantities may result in symptoms of central nervous system depression.

SIGNS AND SYMPTOMS: Symptoms of eye irritation include tearing, reddening, and swelling. Symptoms of skin irritation include reddening, swelling, rash, and redness. Symptoms of gastrointestinal irritation include abdominal pain, vomiting and diarrhea. Symptoms of respiratory irritation include runny nose, sore throat, coughing, chest discomfort, shortness of breath, reduced lung function, and symptoms of central nervous system depression.

AGGRAVATED MEDICAL CONDITIONS: Pre-existing skin, lung, liver, kidney, central nervous system, male reproductive, immune, and auditory systems may be aggravated by exposure to this product.

OTHER HEALTH EFFECTS: Prolonged/repeated exposure may affect the central nervous system. Animal studies have shown fetal harm. The relevance to humans is uncertain. Target organs include the kidneys, liver, spleen, adrenals, lungs, central nervous system, and cardiovascular system.

SECTION 12: ECOLOGICAL INFORMATION

ECOTOXICITY: N/E

DEGRADABILITY: N/E

BIOACCUMULATIVE POTENTIAL: N/E

SOIL MOBILITY: N/E

OTHER ADVERSE EFFECTS: None recognized.

SECTION 13: WASTE DISPOSAL INFORMATION

WASTE DISPOSAL INFORMATION: Product is considered a hazardous waste for disposal purposes. Appropriate for fuel blending/incineration.

SAFETY DATA SHEET

Date of Preparation: 8/12/20 Page 3 of 3 3551-300

SECTION 14: TRANSPORTATION INFORMATION

HAZARDOUS/NON-HAZARDOUS MATERIAL: Hazardous.

UN NUMBER: 1866

HAZARD CLASS: 3

PACKING GROUP: II

UN PROPER SHIPPING NAME: Resin Solution.

ENVIRONMENTAL HAZARDS: Toxic to aquatic organisms. May cause long-term adverse effects in the aquatic environment.

BULK TRANSPORTATION INFORMATION: Not applicable. Product not shipped in bulk configuration.

SPECIAL PRECAUTIONS: Keep containers closed. Avoid ignition sources.

SECTION 15: REGULATORY INFORMATION

OTHER REGULATORY CONSIDERATIONS: None recognized.

SECTION 16: OTHER INFORMATION

PREPARATION DATE: 8/12/2020

PREPARED BY: Dave Carey

The information contained herein is based on the data available to us and is believed to be correct. However, we make no warranty, expressed or implied regarding the accuracy of this data or the results to be obtained from the use thereof. We assume no responsibility for injury from the use of this product described herein.
